Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
RESEARCH TOOLSreports
DRMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $6.67
Previous CloseN/A
Volume28.34K
Average Volume (3M)185.16K
Market Cap
$6.73M
Enterprise Value-$3.59M
Total Cash (Recent Filing)-$1.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 20, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.53
Shares Outstanding5,430,648
10 Day Avg. Volume118,841
30 Day Avg. Volume185,163
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.98
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$6.00Price Target Upside383.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company raised gross proceeds of ~$2.6M in a private placement offering, and it is believed to have sufficient liquidity to last into 2025.
Regulatory MilestoneDRMA has completed patient enrollment and visitations in its initial Phase 3 clinical trial for the treatment of moderate-to-severe acne with Xyngari, a regulatory milestone.
Technology And Market OpportunitiesDespite being an early stage development company, DRMA's unique Spongilla technology and promising clinical acne data justify a price target due to significant opportunities in various treatment markets.
Bears Say
Pre-Revenue StatusDespite being pre-revenue, the company reported lower-than-expected operating expenses and a narrower GAAP loss per share for 3Q24.
---
Ownership Overview
26.87% Insiders
0.16%
Mutual Funds
0.51% Other Institutional Investors
72.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $1.00 and its highest was $6.67 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $6.73M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is May 20, 2025 which is in 56 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on Mar 17, 2025. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.5 by $0.16.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 5,430,648 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.5. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
---
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
---
DRMA Stock 12 Month Forecast
Average Price Target
$6.00
▲(383.87% Upside)
Technical Analysis
Best Analysts Covering DRMA
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-69.75%
reiterated a buy rating 6 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -69.75% per trade.
---